Investor Overview

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and its diverse stakeholders.

We supply medicines to more than 150 countries and have 70 established business operations in 55 countries. We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets.

FAST FACTS

OUR INVESTMENT CASE

Leveraging our strengths and capabilities to deliver long-term shareholder value, while living the Aspen values.

Please click on a title below left for more information.

Responsible corporate citizen and a trusted partner Strategically relevant manufacturing capital Global footprint with a focus on emerging markets Diverse, branded product portfolio Committed management team, strongly aligned with shareholders' interests

Responsible corporate citizen and a trusted partner

We are committed to effective and robust corporate governance making us a trusted partner. Recent high profile corporate challenges have further heightened our attention to governance and we remain committed to continuously improving our reporting, transparency and disclosure.
We are a signatory to the United Nations Global Compact ("UN Global Compact") Initiative.
A constituent of the FTSE/JSE Responsible Investment Index.

Strategically relevant manufacturing capital

Global footprint with a focus on emerging markets

With a strong foundation in the South African market, we now have 70 established business operations, weighted towards emerging markets.
Operating in the highly regulated pharmaceutical sector, our geographic footprint provides diversification of our risk exposure.
Our regional sales force is weighted towards emerging markets, positioning us to benefit from the growth demographics in these territories.

Diverse, branded product portfolio

Our portfolio of products has strong brand equity, supporting the promotion of both our global Sterile and Regional Brands therapeutic segments.
Diversification is achieved through our product portfolio which comprises a basket of related post-patent, branded medicines and domestic brands spanning most therapeutic areas and offering improved health to patients through all stages of life.

Committed management team, strongly aligned with shareholders' interests

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

Aspen Group Unaudited Interim Results presentation for the six months ended 31 December 2019
• PDF 857KB

CAPITAL DISTRIBUTIONS

All capital distributions to date

SHAREHOLDER STATISTICS

Analysis of shareholders at 30 June 2019

CORPORATE INFORMATION

All corporate information and contact details

CONTACT DETAILS

Luresha Chetty
+27 31 580 8637
InvestorRelations@aspenpharma.com

REGISTER FOR ALERTS

WEBCAST

Click here to view the webcast playback of Aspen's interim results for the six months ended 31 December 2019.

INVESTOR CALENDAR

30 June 2020

Financial year end

10 September 2020

Year end results announcement and presentation in Johannesburg

9 December 2020

Annual General Meeting